[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-status-epilepticus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-status-epilepticus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100606567","phase-4-ketamine-for-the-treatment-of-refractory-status-epilepticus-100606567",false,"NCT07177235","Ketamine for the Treatment of Refractory Status Epilepticus","Early Ketamine Plus Midazolam Versus Ketamine Plus Midazolam for the Treatment of Refractory Status Epilepticus","Inclusion Criteria:\n\n1. Adults 18 years of age or older\n2. Patients with refractory status epilepticus unresponsive to appropriately dosed first line agents administered intravenous or intraosseous and one second line agent\n\n   1. First line agents: lorazepam, midazolam, or diazepam\n   2. Second line agents: phenytoin (20 mg\u002Fkg), valproate (40 mg\u002Fkg), levetiracetam (60 mg\u002Fkg), lacosamide (400 mg)\n3. All etiologies of status epilepticus will be included\n\nExclusion Criteria:\n\n1. Exclusively psychogenic non epileptic seizures\n2. Pregnant individuals\n3. Incarcerated individuals\n4. Patients with hypersensitivity to ketamine or any component of the formulation\n5. Conditions in which an increase in blood pressure would be hazardous\n6. Focal motor status epilepticus\n7. Status epilepticus lasting \\> 24 hours prior to enrollment (SRSE)\n8. Patients with EEG in the ictal-interictal continuum (IIC)","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).",[26],"Refractory Status Epilepticus","NOT_YET_RECRUITING","2025-09-09",{"date":30,"type":31},"2025-09-16","ACTUAL",{"date":33,"type":20},"2025-11",{"date":35,"type":20},"2028-07",{"name":37,"class":38},"Thomas Jefferson University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100504673","phase-2-burst-suppression-to-stop-refractory-status-epilepticus-post-cardiac-arrest-100504673","NCT05851391","buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest","buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)","RESTORE","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Non-traumatic, out-of-hospital cardiac arrest\n3. Comatose on admission - defined as not following commands\n4. Return of spontaneous circulation (ROSC) within less than 45 minutes\n5. Admission to the intensive care unit\n6. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous\n\nEEG monitoring within 7 days from ROSC\n\nExclusion Criteria:\n\n1. Acute cerebral hemorrhage or infarction\n2. Pregnancy\n3. Prisoners",{"count":49,"type":20},30,[51],"PHASE2","RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.",[54,55,56,26,57,58,59],"Hypoxia-Ischemia, Brain","Heart Arrest","Status Epilepticus","Seizures","Anoxic-Ischemic Encephalopathy","Anoxia-Ischemia, Cerebral","RECRUITING","2025-05-12",{"date":63,"type":31},"2025-05-15",{"date":65,"type":31},"2023-08-07",{"date":67,"type":20},"2027-04-30",{"name":69,"class":38},"University of California, San Francisco",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":39},"100542551","application-of-tdcs-stimulation-in-controlling-refractory-status-epilepticus-100542551","NCT06344338","Application of tDCS Stimulation in Controlling Refractory Status Epilepticus","Application of Targeting Transcranial Direct Current Stimulation (tDCS) Stimulation in the Treatment of Refractory Status Epilepticus","tDCS","Inclusion Criteria:\n\n* Age between 14 and 80 year-old with Gender unlimited,\n* Suitable for EEG monitoring;\n* Clinical diagnosis of Refractory status epilepticus (status epilepticus that cannot be controlled by two types of antiepileptic drugs and at least one anesthetic);\n* Informed consent to participate in this study was obtained from the participants or their surrogates\n\nExclusion Criteria:\n\n* Unstable vital signs (systolic blood pressure\\\u003C90mmHg, heart rate\\\u003C60 beats\u002Fmin, pulse oxygen saturation\\\u003C90%);\n* Having severe skull injury\u002Fdefect or medical equipment implanted in the head;\n* Pregnancy;\n* With any implantable electronic instrument (including pacemakers, vagus nerve stimulators) or metal implanted devices.","14 Years","80 Years",{"count":81,"type":20},32,[83],"NA","The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus",[26],"2024-07-30",{"date":88,"type":31},"2024-07-31",{"date":90,"type":31},"2024-04-01",{"date":92,"type":20},"2025-03-31",{"name":94,"class":38},"Xuanwu Hospital, Beijing"]